Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
This study has been terminated.
(Slow accrual and company withdrawing support to supply the drug)
Sponsor:
Pediatric Brain Tumor Consortium
Collaborator:
Information provided by:
Pediatric Brain Tumor Consortium
ClinicalTrials.gov Identifier:
NCT00112619
First received: June 2, 2005
Last updated: June 29, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of topotecan when given by intraventricular infusion in treating young patients with neoplastic meningitis due to leukemia, lymphoma, or solid tumors.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain and Central Nervous System Tumors Carcinoma of Unknown Primary Leukemia Lymphoma Unspecified Childhood Solid Tumor, Protocol Specific |
Drug: topotecan hydrochloride |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis |
Resource links provided by NLM:
Further study details as provided by Pediatric Brain Tumor Consortium:
Primary Outcome Measures:
- Estimate the maximum tolerated dose of intraventricular topotecan on this schedule [ Time Frame: First 14 days of therapy ] [ Designated as safety issue: Yes ]
- Number of patients with dose-limiting toxicity [ Time Frame: First 14 days of therapy ] [ Designated as safety issue: Yes ]
- Estimate the dose of intraventricular topotecan that will result in cerebrospinal fluid lactone concentrations exceeding 1 ng/mL for at least 8 hours after an intrathecal injection [ Time Frame: Day 1 of Week 1 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Number of patients with objective documentation of tumor response to intraventricular topotecan [ Time Frame: Weeks 5, 11 and then every 12 weeks until off study ] [ Designated as safety issue: No ]MRI of the brain and spine is obtained pre-consolidation, pre-maintenance, and then every 12 weeks in maintenance.
- Pharmacokinetics [ Time Frame: Day 1 of Week 1 ] [ Designated as safety issue: No ]The cerebrospinal fluid (CSF) concentration-time profile for topotecan after intrathecal CSF administration will be modeled from the CSF samples collected on day 1 of week 1. Individual pharmacokinetic parameters estimated will include volume of central compartment, elimination rate constant, half-life, and clearance.
- Correlation of imaging parameters with tumor response [ Time Frame: Pre-treatment, week 5, week 11, and then every 12 weeks until off study ] [ Designated as safety issue: No ]MRI scans of the brain and spine is obtained pre-treament, pre-consolidation, pre-maintenance, and then every 12 weeks on maintenance.
| Enrollment: | 19 |
| Study Start Date: | August 2005 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Intervention Details:
Detailed Description:
-
Drug: topotecan hydrochloride
Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).
Other Name: Hycamptin
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD) of intraventricular topotecan in young patients with neoplastic meningitis secondary to leukemia, lymphoma, or solid tumors.
- Determine the toxic effects and dose-limiting toxicity of this drug in these patients.
- Determine whether the MTD of this drug is also the pharmacokinetic optimal dose, defined by the topotecan lactone concentration in the cerebral spinal fluid (CSF), in these patients.
Secondary
- Determine, preliminarily, the antitumor activity of this drug in these patients.
- Determine the pharmacokinetics of this drug in the CSF of these patients.
- Correlate observed effects of post-treatment central review imaging (if feasible) with response to this drug in these patients.
OUTLINE: This is a non-randomized, dose-escalation, multicenter study.
- Induction therapy (weeks 1-4): Patients receive topotecan intraventricularly* over 5 minutes on days 1-5 in weeks 1 and 3. Patients then proceed to consolidation therapy in week 5.
NOTE: *Patients who are willing, receive 1 intralumbar (instead of intraventricular) dose of topotecan on day 1 of week 3 only.
- Consolidation therapy (weeks 5-10): Patients receive topotecan intraventricularly on days 1-5 in weeks 5 and 8. Patients then proceed to maintenance therapy in week 11.
- Maintenance therapy (weeks 11-54): Patients receive topotecan intraventricularly on days 1-5 in weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51.
Cohorts of 3-6 patients receive escalating doses of intraventricular topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Once the MTD is determined, the cohort is expanded to 25 patients and the MTD is declared the pharmacokinetic optimal dose provided 23 of 25 patients treated at the MTD achieve the target pharmacokinetic parameter.
PROJECTED ACCRUAL: A total of 28-49 patients will be accrued for this study within 9-24 months.
Eligibility| Ages Eligible for Study: | 3 Years to 21 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
Diagnosis of neoplastic meningitis secondary to leukemia, lymphoma (including AIDS-related lymphoma), or solid tumor (including primary CNS tumors or carcinomas of unknown primary site), defined by 1 of the following criteria:
- Cerebral spinal fluid (CSF) cell count > 5/μL AND evidence of blast cells on cytospin or by cytology (for patients with leukemia or lymphoma)
- Presence of tumor cells on cytospin or cytology OR unequivocal presence of meningeal disease by MRI (for patients with solid tumor)
No conventional therapy for neoplastic meningitis exists
- Patients with CNS leukemia or lymphoma must be refractory to conventional therapy, including radiotherapy (i.e., second or greater relapse)
- Patients with CNS leukemia or lymphoma must have had a negative bone marrow aspiration within the past 2 weeks
- No clinical evidence of obstructive hydrocephalus
- No compartmentalization of CSF flow by radioisotope indium In 111 or technetium Tc 99 DTPA flow study
- No ventriculoperitoneal or ventriculoatrial shunt unless patient is completely shunt-independent
- No impending spinal cord compression or other CNS involvement (e.g., acute visual loss secondary to optic nerve involvement) requiring emergent local radiotherapy
PATIENT CHARACTERISTICS:
Age
- 3 to 21
Performance status
- Lansky 60-100% (≤ 16 years of age) OR
- Karnofsky 60-100% (> 16 years of age)
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Calcium ≥ 7 mg/dL
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Sodium 125-150 mmol/L
- Magnesium ≥ 0.7 mmol/L
- Must have or be willing to have an intraventricular access device (i.e., Ommaya reservoir)
No uncontrolled infection
- HIV-positive patients with AIDS-related lymphomatous meningitis are eligible
- No other significant uncontrolled systemic medical illness that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Recovered from prior biologic therapy or immunotherapy
Chemotherapy
- Recovered from prior chemotherapy
- At least 1 week since prior intra-colony stimulating factory (CSF) chemotherapy (2 weeks for liposomal cytarabine)
- At least 3 weeks since prior systemic chemotherapy for leptomeningeal disease
Concurrent systemic chemotherapy to control systemic disease or bulk CNS disease allowed provided the systemic chemotherapy is not an investigational agent OR any of the following:
- High-dose (> 1 g/m^2) methotrexate
- High-dose (> 1 g/m^2) cytarabine
- Fluorouracil
- Capecitabine
- Thiotepa
- Nitrosoureas
- Topotecan
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- At least 8 weeks since prior craniospinal radiotherapy and recovered
No concurrent CNS radiotherapy
- Concurrent radiotherapy to extra-CNS sites (e.g., painful bone metastases not in the craniospinal axis) allowed
Surgery
- Not specified
Other
- More than 2 weeks since prior and no other concurrent investigational agents
- No other concurrent intra-CSF or systemic therapy for leptomeningeal disease
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00112619
Locations
| United States, California | |
| UCSF Helen Diller Family Comprehensive Cancer Center | |
| San Francisco, California, United States, 94115 | |
| United States, District of Columbia | |
| Children's National Medical Center | |
| Washington, District of Columbia, United States, 20010-2970 | |
| United States, Illinois | |
| Children's Memorial Hospital - Chicago | |
| Chicago, Illinois, United States, 60614 | |
| United States, Maryland | |
| Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | |
| Bethesda, Maryland, United States, 20892-1182 | |
| United States, Massachusetts | |
| Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute | |
| Boston, Massachusetts, United States, 02115 | |
| United States, North Carolina | |
| Duke Comprehensive Cancer Center | |
| Durham, North Carolina, United States, 27710 | |
| United States, Pennsylvania | |
| Children's Hospital of Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104-4318 | |
| Children's Hospital of Pittsburgh | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Tennessee | |
| St. Jude Children's Research Hospital | |
| Memphis, Tennessee, United States, 38105 | |
| United States, Texas | |
| Dan L. Duncan Cancer Center at Baylor College of Medicine | |
| Houston, Texas, United States, 77030 | |
| United States, Washington | |
| Children's Hospital and Regional Medical Center - Seattle | |
| Seattle, Washington, United States, 98105 | |
Sponsors and Collaborators
Pediatric Brain Tumor Consortium
Investigators
| Study Chair: | Susan M. Blaney, MD | Baylor College of Medicine |
More Information
No publications provided
| Responsible Party: | James M. Boyett, Executive Director Operations and Biostatistics Center, Pediatric Brain Tumor Consortium |
| ClinicalTrials.gov Identifier: | NCT00112619 History of Changes |
| Other Study ID Numbers: | CDR0000430504, U01CA081457, PBTC-019 |
| Study First Received: | June 2, 2005 |
| Last Updated: | June 29, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Pediatric Brain Tumor Consortium:
|
AIDS-related diffuse large cell lymphoma AIDS-related diffuse mixed cell lymphoma AIDS-related diffuse small cleaved cell lymphoma AIDS-related immunoblastic large cell lymphoma AIDS-related lymphoblastic lymphoma AIDS-related peripheral/systemic lymphoma AIDS-related primary CNS lymphoma AIDS-related small noncleaved cell lymphoma HIV-associated Hodgkin lymphoma stage IV childhood Hodgkin lymphoma stage IV childhood large cell lymphoma stage IV childhood lymphoblastic lymphoma stage IV childhood small noncleaved cell lymphoma primary central nervous system non-Hodgkin lymphoma primary central nervous system Hodgkin lymphoma |
recurrent childhood acute lymphoblastic leukemia recurrent childhood acute myeloid leukemia unspecified childhood solid tumor, protocol specific childhood grade I meningioma childhood grade II meningioma childhood grade III meningioma recurrent childhood cerebellar astrocytoma recurrent childhood cerebral astrocytoma childhood high-grade cerebral astrocytoma childhood low-grade cerebral astrocytoma childhood choroid plexus tumor childhood craniopharyngioma childhood infratentorial ependymoma childhood supratentorial ependymoma recurrent childhood ependymoma |
Additional relevant MeSH terms:
|
Carcinoma Leukemia Lymphoma Meningitis Nervous System Neoplasms Lymphoma, Non-Hodgkin Central Nervous System Neoplasms Neoplasms, Unknown Primary Meningeal Carcinomatosis Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders |
Immune System Diseases Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases Neoplasms by Site Neoplasm Metastasis Neoplastic Processes Pathologic Processes Meningeal Neoplasms Topotecan Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on February 24, 2013
